Reference is made to the stock exchange release from SoftOx Solutions AS (the “Company”) on 28 November 2025 regarding the board resolution to increase the share capital by carrying out a private placement of NOK 3 624 000 under the financing facility with the investment fund Long State Investments Limited (“Long State”).
The new share capital, following completion of the private placement, has today been registered with the Norwegian Register of Business Enterprises.
…
Vis børsmeldingen
The new share capital of the Company is NOK 47 808 339.88 divided into 2 390 416 994 shares, each with a par value of NOK 0.02.
For more information on the financing facility, please see the Company’s stock exchange release dated 14 September 2025.
For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com
About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.
Kilde
